A tool to balance benefit and harm when deciding about adjuvant therapy

Por Knops, A M, Goossens, A, Burger, M P M, Stalpers, L J A, Ubbink, D T
Publicado em 2009

O1.01 ESTIMATION OF THE INCIDENCE OF BRAIN METASTASES AND PATTERNS OF CARE IN THE NETHERLANDS

Por Kwakman, R.J.J.M., Jeene, P.M., Dieleman, E.M.T., Stalpers, L.J.A.
Publicado em 2014

Biological modelling of the radiation dose escalation effect of regional hyperthermia in cervical cancer

Por Crezee, J., van Leeuwen, C. M., Oei, A. L., van Heerden, L. E., Bel, A., Stalpers, L. J. A., Ghadjar, P., Franken, N. A. P., Kok, H. P.
Publicado no Radiat Oncol (2016)

Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor

Por Hoebers, F. J. P., Pluim, D., Hart, A. A. M., Verheij, M., Balm, A. J. M., Fons, G., Rasch, C. R. N., Schellens, J. H. M., Stalpers, L. J. A., Bartelink, H., Begg, A. C.
Publicado em 2007

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide

Por van Nifterik, K A, van den Berg, J, van der Meide, W F, Ameziane, N, Wedekind, L E, Steenbergen, R D M, Leenstra, S, Lafleur, M V M, Slotman, B J, Stalpers, L J A, Sminia, P
Publicado em 2010